MedImmune Ventures appoints Ron Laufer

pharmafile | June 18, 2010 | Appointment | Research and Development AstraZeneca, MedImmune, appointment, research and development 

Ron Laufer has joined MedImmune’s venture capital arm as senior managing director.

The company, which is the worldwide biologics unit for AstraZeneca, said Laufer wold strengthen its long-term commitment to supporting scientific innovation through strategic venture capital investments.

“I am delighted to join MedImmune Ventures at this exciting time in biopharmaceutical research,” said Laufer. “I look forward to building on a successful history and supporting promising products and companies as they pursue our shared commitment to improving patient health.”

Laufer has more than 15 years industry experience, during which he co-founded Lilly Ventures, Eli Lilly and Company’s corporate venture capital fund.

He was also a managing director for healthcare-focused investment firm Visium Asset Management.

Related Content


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

LaNova Medicines and AstraZeneca sign global exclusive license agreement for preclinical ADC

Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have …

Latest content